CASSIDY KUJALA: Open Payments
NPI 1336918002 · GRIFFIN, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$738 in 34 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $1,067 · 2025 $738
Food & beverage: $738
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $195 |
| Novartis Pharmaceuticals Corporation | 4 | $81 |
| AstraZeneca Pharmaceuticals LP | 3 | $64 |
| Daiichi Sankyo Inc. | 2 | $50 |
| Lilly USA, LLC | 2 | $47 |
| SOBI, INC | 2 | $46 |
| Karyopharm Therapeutics Inc. | 2 | $42 |
| PFIZER INC. | 2 | $41 |
| GENZYME CORPORATION | 1 | $32 |
| Tempus AI, Inc | 1 | $27 |
Products named: VENCLEXTA, Enhertu, VERZENIO, Doptelet, XPOVIO, SARCLISA, Fabhalta, XT CDX.
Industry payments across GA — which companies pay providers there.
